About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
The Inflation Reduction Act (IRA) took important steps to lower costs for some patients by capping annual out-of-pocket costs and allowing beneficiaries to spread their costs over the course of the year in Medicare Part D. Unfortunately, the IRA’s price setting policies do more harm than good for many patients. In particular, the negative impacts are most likely to be felt by underserved communities, who disproportionately bear the burden of many illnesses. This is a system-level miss by Congress that further cements health inequities in the United States.
The Inflation Reduction Act's price setting policies do more harm than good for underserved communities. image
Download Printable IRA Equity Profile (English)
Download Digital IRA Equity Profile
Download Digital IRA Equity Profile (Spanish)
Report
The Inflation Reduction Act's price setting policies do more harm than good for underserved communities.
The Inflation Reduction Act's price setting policies do more harm than good for underserved communities. image